ATL names new division SonoSight

Article

ATL Ultrasound has announced that the distribution date for its handheld division took place on April 6 (SCAN 3/18/98). The new company, called SonoSight, will trade on the NASDAQ National Market under the ticker symbol SONO. ATL Ultrasound

ATL Ultrasound has announced that the distribution date for its handheld division took place on April 6 (SCAN 3/18/98). The new company, called SonoSight, will trade on the NASDAQ National Market under the ticker symbol SONO. ATL Ultrasound shareholders of record on March 30 will receive one share of SonoSight for every three shares held of ATL.

SonoSight has filed a 510(k) premarket notification for its first product, with commercial launch anticipated in 1999, according to ATL. A prototype of the first handheld system, targeted for use in women's healthcare, is expected within a few months. Other models are being developed for internal and emergency medical use.

In other SonoSight developments, Kevin Goodwin has been tapped as president and CEO of the company, with Kirby Cramer serving as chairman. Cramer is a member of the ATL board of directors and president of investment firm Keystone Capital Company.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.